65,437 trials
Peripheral Artery Disease · Vascular Function · Exercise Tolerance
Primary: Peripheral Arterial Stiffness — 12.3; 10.2; 12.4; 12.8 meters per second
Dengue Fever · Dengue Hemorrhagic Fever · Human Papillomavirus Disease
Primary: Geometric Mean Titers (GMTs) Against Each Cervarix Human Papillomavirus (HPV) Antigen (HPV-16 and HPV-18) 28 Days After Last Cervarix Vaccination in the Previously…
Cystic Fibrosis
Primary: Change From Baseline in Total Chloride Transport at Day 14 of Cycles 1 and 2 — 1.45; 0.66; -2.81; -2.69 millivolts (mV) — p=0.133
Cognitive Impairment · Metastatic Malignant Neoplasm in the Brain · Solid Neoplasm
Primary: Time to Neurocognitive Failure — 68.2; 59.3 percentage of participants — p=0.029
Pain
Primary: Pain Score on Movement (Sitting in Bed From a Supine Position) — 5; 5 score on a scale
Hypervolemic and Euvolemic Hyponatremia
Primary: Safety Measure — 17.37 percentage of AE
Osteoarthritis, Hip
Primary: DEXA Analysis of BMD at Preoperative Visit — 0.8; 1.0; 1.6; 2.0 g/cm^2
Cervix Cancer · Cervix Lesion
Primary: Short-term Safety Concerns for Ablative Treatment — 288; 106; 100; 31 participants
Endometrial Endometrioid Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma · Endometrial Serous Adenocarcinoma
Primary: Frequency of Objective Response Defined by RECIST 1.1 Criteria — 0.0 percentage of participants
Human Papillomavirus
Primary: Prevalence of Penile HPV Genotypes — 2.6; 0.7; 21.7; 11.6 percentage of participants
Duct Cell Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage III Pancreatic Cancer
Primary: Number of Dose Limiting Toxicities (DLTs) Seen in Patients With Pancreas Adenocarcinoma Treated With Ipilimumab and Gemcitabine Combination in Order to Define the…
Stroke
Primary: Gait Speed — 0.51 meters per second
Iron Deficiency Anaemia · Iron Deficiency Anemia · Chronic Kidney Disease
Primary: Change in Hemoglobin (Hb) From Baseline to Week 8 — 1.22; 1.14 g/dL
Oral Sedation and Cervical Dilator Pain
Primary: Cervical Dilator Placement Pain as Assessed by VAS on a Tablet Device — 55; 44 units on a scale
Breast Cancer
Primary: Clinical Response Rate (cRR) — 6; 18; 5; 0 participants